Related Experiment Video
Updated: May 3, 2026
Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
Effect of landiolol hydrochloride after off-pump coronary artery bypass
Kazuma Maisawa1, Kenji Yamazaki, Hiroshi Ishitoya
1Department of Cardiovascular Surgery, Saitama City Hospital, Saitama City, Saitama, Japan.
Insights
Landiolol, an intravenous beta blocker, significantly reduced the incidence of atrial fibrillation after off-pump coronary artery bypass surgery. This intravenous beta blocker also lowered heart rate and inflammatory markers post-surgery.
Area of Science:
- Cardiology
- Cardiac Surgery
- Pharmacology
Background:
- Oral beta-blockers are known to reduce atrial fibrillation post-coronary artery bypass.
- The efficacy of intravenous beta-blockers, specifically landiolol, in this context remains less explored.
Purpose of the Study:
- To investigate the effectiveness of landiolol in preventing atrial fibrillation after off-pump coronary artery bypass (OPCAB).
Main Methods:
- A prospective study involving 39 patients receiving landiolol post-OPCAB versus 20 control patients.
- Landiolol was administered intravenously at a dose of 1 µg.kg(-1).min(-1) in the intensive care unit.
Main Results:
- The incidence of atrial fibrillation was significantly lower in the landiolol group (2.6%) compared to the control group (20%).
- Landiolol administration led to a significant reduction in heart rate without affecting blood pressure.
- Post-operative C-reactive protein and creatine kinase levels were lower in the landiolol group.
Conclusions:
- Continuous, low-dose landiolol administration effectively reduces atrial fibrillation incidence following OPCAB.
- Landiolol may also mitigate post-operative inflammation and cardiac enzyme release.
Objectives:
many studies have shown that oral beta blockers reduce the incidence of atrial fibrillation after coronary artery bypass. The goal of this study was to determine whether landiolol, an intravenous beta blocker, reduces the incidence of atrial fibrillation after off-pump coronary artery bypass.
Methods:
39 consecutive patients were given landiolol after coronary artery bypass, and 20 who were not given landiolol served as a control group. Landiolol was intravenously administered at 1 µg.kg(-1).min(-1) in the intensive care unit.
Results:
the mean dose of landiolol was 2.3 ± 1.2 1 µg.kg(-1).min(-1). The incidence of atrial fibrillation during intensive care unit stay was significantly lower in the landiolol group compared to the control group: 2.6% (1/39) vs. 20% (4/20). Heart rate after landiolol administration was significantly lower than that before administration, whereas landiolol had no effect on blood pressure. C-reactive protein and creatine kinase levels 7 days after surgery were significantly lower in the landiolol group.
Conclusion:
continuous administration of landiolol at a low dose after off-pump coronary artery bypass reduced the incidence of atrial fibrillation.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:26Heart Failure Drugs: Inotropic Agents